FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033991682> ?p ?o ?g. }

• W3033991682 endingPage "1537" @default.
• W3033991682 startingPage "1522" @default.
• W3033991682 abstract "Significance Statement Nephropathic cystinosis, the most severe form of the lysosomal storage disease cystinosis, presents as renal Fanconi syndrome. Defective cystine transport leads to intralysosomal accumulation and crystallization of cystine. The only treatment for cystinosis, cysteamine, does not correct the Fanconi syndrome or prevent progression to ESKD, suggesting involvement of pathways unrelated to lysosomal cystine accumulation. The authors used high-throughput screening to identify molecules that reduce accumulation of the autophagy substrate p62/SQSTM1 in cystinotic proximal tubular epithelial cells and restore normal autophagy. Studies in cells derived from patients with, or mouse models of, cystinosis and in cystinotic zebrafish indicate that luteolin corrects aspects of the cystinotic phenotype that are linked to renal Fanconi syndrome. These findings provide new perspectives for the treatment of nephropathic cystinosis and other renal lysosomal storage diseases. Background Mutations in the gene that encodes the lysosomal cystine transporter cystinosin cause the lysosomal storage disease cystinosis. Defective cystine transport leads to intralysosomal accumulation and crystallization of cystine. The most severe phenotype, nephropathic cystinosis, manifests during the first months of life, as renal Fanconi syndrome. The cystine-depleting agent cysteamine significantly delays symptoms, but it cannot prevent progression to ESKD and does not treat Fanconi syndrome. This suggests the involvement of pathways in nephropathic cystinosis that are unrelated to lysosomal cystine accumulation. Recent data indicate that one such potential pathway, lysosome-mediated degradation of autophagy cargoes, is compromised in cystinosis. Methods To identify drugs that reduce levels of the autophagy-related protein p62/SQSTM1 in cystinotic proximal tubular epithelial cells, we performed a high-throughput screening on the basis of an in-cell ELISA assay. We then tested a promising candidate in cells derived from patients with, and mouse models of, cystinosis, and in preclinical studies in cystinotic zebrafish. Results Of 46 compounds identified as reducing p62/SQSTM1 levels in cystinotic cells, we selected luteolin on the basis of its efficacy, safety profile, and similarity to genistein, which we previously showed to ameliorate other lysosomal abnormalities of cystinotic cells. Our data show that luteolin improves the autophagy–lysosome degradative pathway, is a powerful antioxidant, and has antiapoptotic properties. Moreover, luteolin stimulates endocytosis and improves the expression of the endocytic receptor megalin. Conclusions Our data show that luteolin improves defective pathways of cystinosis and has a good safety profile, and thus has potential as a treatment for nephropathic cystinosis and other renal lysosomal storage diseases." @default.
• W3033991682 created "2020-06-12" @default.
• W3033991682 creator A5001918427 @default.
• W3033991682 creator A5003384538 @default.
• W3033991682 creator A5003582055 @default.
• W3033991682 creator A5004141793 @default.
• W3033991682 creator A5006335450 @default.
• W3033991682 creator A5008945877 @default.
• W3033991682 creator A5010533721 @default.
• W3033991682 creator A5020182729 @default.
• W3033991682 creator A5025899204 @default.
• W3033991682 creator A5026027226 @default.
• W3033991682 creator A5028156101 @default.
• W3033991682 creator A5031053578 @default.
• W3033991682 creator A5033792420 @default.
• W3033991682 creator A5042423268 @default.
• W3033991682 creator A5054538151 @default.
• W3033991682 creator A5060914864 @default.
• W3033991682 creator A5071866690 @default.
• W3033991682 creator A5074407431 @default.
• W3033991682 creator A5091523943 @default.
• W3033991682 date "2020-06-05" @default.
• W3033991682 modified "2023-10-12" @default.
• W3033991682 title "Cell-Based Phenotypic Drug Screening Identifies Luteolin as Candidate Therapeutic for Nephropathic Cystinosis" @default.
• W3033991682 cites W1462606079 @default.
• W3033991682 cites W1915211640 @default.
• W3033991682 cites W1926761645 @default.
• W3033991682 cites W1963736118 @default.
• W3033991682 cites W1970760700 @default.
• W3033991682 cites W1976348649 @default.
• W3033991682 cites W1984314492 @default.
• W3033991682 cites W1989314175 @default.
• W3033991682 cites W1991001144 @default.
• W3033991682 cites W1996130473 @default.
• W3033991682 cites W2008823943 @default.
• W3033991682 cites W2011313278 @default.
• W3033991682 cites W2011597935 @default.
• W3033991682 cites W2013629587 @default.
• W3033991682 cites W2015894449 @default.
• W3033991682 cites W2018621678 @default.
• W3033991682 cites W2025325512 @default.
• W3033991682 cites W2038053883 @default.
• W3033991682 cites W2042029593 @default.
• W3033991682 cites W2062002123 @default.
• W3033991682 cites W2079292289 @default.
• W3033991682 cites W2079766707 @default.
• W3033991682 cites W2095686007 @default.
• W3033991682 cites W2097470651 @default.
• W3033991682 cites W2100420463 @default.
• W3033991682 cites W2106652794 @default.
• W3033991682 cites W2106868787 @default.
• W3033991682 cites W2109044503 @default.
• W3033991682 cites W2116060738 @default.
• W3033991682 cites W2136231279 @default.
• W3033991682 cites W2139285220 @default.
• W3033991682 cites W2152545043 @default.
• W3033991682 cites W2161718127 @default.
• W3033991682 cites W2164340284 @default.
• W3033991682 cites W2166434963 @default.
• W3033991682 cites W2171320890 @default.
• W3033991682 cites W2171880801 @default.
• W3033991682 cites W2172282890 @default.
• W3033991682 cites W2284379088 @default.
• W3033991682 cites W2301961318 @default.
• W3033991682 cites W2341643196 @default.
• W3033991682 cites W2474023059 @default.
• W3033991682 cites W2521162882 @default.
• W3033991682 cites W2565280039 @default.
• W3033991682 cites W2588039664 @default.
• W3033991682 cites W2593558289 @default.
• W3033991682 cites W2621725158 @default.
• W3033991682 cites W2728274349 @default.
• W3033991682 cites W2781502062 @default.
• W3033991682 cites W2792486305 @default.
• W3033991682 cites W2803904939 @default.
• W3033991682 cites W2887741162 @default.
• W3033991682 cites W2892087768 @default.
• W3033991682 cites W2902721160 @default.
• W3033991682 cites W2976103401 @default.
• W3033991682 cites W2997380075 @default.
• W3033991682 doi "https://doi.org/10.1681/asn.2019090956" @default.
• W3033991682 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7351012" @default.
• W3033991682 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32503896" @default.
• W3033991682 hasPublicationYear "2020" @default.
• W3033991682 type Work @default.
• W3033991682 sameAs 3033991682 @default.
• W3033991682 citedByCount "15" @default.
• W3033991682 countsByYear W30339916822021 @default.
• W3033991682 countsByYear W30339916822022 @default.
• W3033991682 countsByYear W30339916822023 @default.
• W3033991682 crossrefType "journal-article" @default.
• W3033991682 hasAuthorship W3033991682A5001918427 @default.
• W3033991682 hasAuthorship W3033991682A5003384538 @default.
• W3033991682 hasAuthorship W3033991682A5003582055 @default.
• W3033991682 hasAuthorship W3033991682A5004141793 @default.
• W3033991682 hasAuthorship W3033991682A5006335450 @default.
• W3033991682 hasAuthorship W3033991682A5008945877 @default.
• W3033991682 hasAuthorship W3033991682A5010533721 @default.

• next